Guillaume Pfefer, Sail Biomedicines CEO

Up­dat­ed: Flag­ship merges its trou­bled cir­cu­lar RNA com­pa­ny Laronde with nanopar­ti­cle start­up Sen­da

Laronde and Sen­da Bio­sciences, two biotech star­tups found­ed by Flag­ship Pi­o­neer­ing that col­lec­tive­ly raised more than $750 mil­lion, are merg­ing to form a new com­pa­ny called Sail Bio­med­i­cines, the life sci­ence in­vest­ment group an­nounced Thurs­day morn­ing.

Sail will com­bine Laronde’s cir­cu­lar RNA tech­nol­o­gy with Sen­da’s na­ture-de­rived nanopar­ti­cle plat­form. It’s a nat­ur­al pair­ing, since one of the biggest chal­lenges fac­ing ge­net­ic med­i­cines is find­ing new ways to de­liv­er them to the right cells in the body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.